As we seek to build a diversified portfolio of 20-25 companies, some companies may not succeed and we may receive attractive offers for our companies from third parties.
The Syncona team have significant experience in managing risk and reward in a specialised asset class and has a proven track record in delivering attractive risk adjusted return for our shareholders. To date, we have divested five Syncona portfolio companies (Gyroscope, Blue Earth, Nightstar, Neogene and Clade), generating proceeds of £955 million, and two companies have not succeeded (Azeria and 14MG). Syncona has been able to redeploy these proceeds in new opportunities based on exceptional science in line with our capital allocation focus to maximise value for shareholders.
Our previous portfolio companies
